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Neuroinflammation has been implicated in Alzheimer’s disease onset and progression. Chronic 
neuroinflammation is initiated by amyloid beta-activated microglial cells that secrete immuno- 
modulatory molecules within the brain and into the vasculature. Inflammation is normally self-
limiting and actively resolves by “switching off” the generation of pro-inflammatory mediators and 
by non-phlogistic clearance of spent cells and their debris to restore tissue homeostasis. Deficits in 
these anti-inflammatory/pro-resolution pathways may predispose to the development of chronic 
inflammation.  The synthesis of endogenous lipid mediators from arachidonic acid (AA), lipoxins via 
cyclooxygenase 2 and lipoxygenases, and conversion of exogenous polyunsaturated fatty acids, 
namely docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) to resolvins contributes to 
effective, timely resolution of acute inflammation.  
Work by Xiuzhe et al., 2020 in the Journal of Alzheimer’s Disease (AD) reported that plasma level of 
LXA4 is related to cognitive status in ischemic stroke patients suggesting that decreased LXA4 may be 
a potential risk factor for post post-stroke cognitive impairment. As evident by recent clinical trials 
and development of drug analogues, there is recent drive to search for lipoxin analogues as 
therapeutics for inflammatory diseases. Understanding how bioactive lipid signalling is involved in 
resolution will increase our understanding of controlling inflammation and may facilitate the 










Commentary   
The initiation of an inflammatory response and its timely resolution is critical to maintain a healthy 
physiological state. When the resolution of inflammation is compromised, homeostasis may be 
skewed towards chronic inflammatory status resulting in bystander tissue damage. Emerging 
evidence over the last decade suggested that the presence of a sustained immune response in the 
brain is a common pathology in Alzheimer’s disease (AD) [1, 2]. The interaction of microglia and 
other brain resident immune cells with fibrillar amyloid beta (Aβ) may lead to their activation and 
the conversion of these cells into a classically ‘activated’ phenotype producing of chemokines, 
neurotoxic cytokines, eicosanoids and reactive oxygen (ROS) and nitrogen species (RNS) that are 
deleterious to the central nervous system [3]. Moreover, a role for inflammation in AD has gained 
strong support from genome-wide association studies that have identified genes involved in 
inflammation that are associated with increased risk of developing AD [4, 5]. While 
neuroinflammation is elicited to clear “damage” and initiate repair processes, uncontrolled 
inflammation can result in neurotoxicity that exacerbates a neurodegenerative pathology. However, 
merely inhibiting the inflammatory response may weaken its protective effect and potentially be 
more detrimental. Therefore, a deeper understanding of the resolution of inflammation generally 
and AD is needed to enable its protective while minimising its detrimental effects. 
It is now recognised that resolution of inflammation is a dynamically regulated, active process that is 
orchestrated by specialised pro-resolving lipid mediators (SPMs) such as lipoxins, resolvins, 
protectins and maresins. These SPMs are enzymatically synthesised from essential polyunsaturated 
fatty acids namely docosahexaenoic acid (DHA; 22:6 ω3), eicosapentaenoic acid (EPA; 22:5 ω3) and 
arachidonic acid (AA; 20:4 ω6) via sequential steps involving cyclooxygenase (COX) and lipoxygenase 
(LOX) enzymes [6]. AA and DHA can be metabolised by lipoxygenases to form hydroxy derivatives 
and leukotrienes and AA is metabolised by cyclooxygenases to prostaglandins and thromboxanes or 
lipoxins via sequential lipoxygenase activity. Lipoxins (LXA4 and LXB4) are generated by two main 
routes in circulating immune cells. The first described route inserts molecular oxygen to AA by 15-
LOX followed by 5-LOX based transformation. The second route involves the conversion of 5-LOX-
derived LTA4 and subsequent conversion to lipoxins via 12-LOX activity [7]. The generation of 
lipoxins is known to increase during cell-cell interactions in blood and mucosal tissues. When both 
15-LOX and 5-LOX are co-expressed, the biosynthesis of lipoxins can occur in the same cell such as in 
eosinophils, macrophages and resolution phase neutrophils [8, 9]. They have been reported to act at 
both temporal and spatially distinct sites from other eicosanoids produced during the inflammatory-
resolution process. However, it is still unclear how lipoxins are formed within the intact human brain 
and in pathological conditions. 
Epidemiological studies of non-steroidal anti-inflammatory drug (NSAID) interventions have 
suggested their use may delay disease onset [10, 11] providing support for inflammation in the 
aetiology of AD. A meta-analysis study has revealed as much as 50% reduction in the risk of disease 
onset among chronic none steroidal anti-inflammatory drugs (NSAID) users [12].  NSAIDs exert their 
anti-inflammatory effect by either inhibiting the COX-2 pathway or modifying COX-2 to promote 
biosynthesis of SPMs. For example, aspirin triggers acetylation of cyclooxygenase-2 to increase 
lipoxin production [7]. This inducible enzyme increases the synthesis of the pro-inflammatory 
mediators, PG from dietary or membrane-originated AA via phospholipase A2 activity. NSAIDs inhibit 
the COX-2 enzyme without affecting 5-LOX activity and do not prevent the formation of leukotrienes 
(LTs). Elevated 5-LOX mediated AA metabolism and accumulation of cysteinyl LTs, such as LTC4, 
LTD4, LTE4, and leuko-attractive LTB4 are observed in several organs including the brain of mammals 
in response to NSAID consumption [13]. 
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The positive outcome of a number of small (n~50) pilot intervention studies over 3-6 months to 
address the hypothesis that chronic NSAID use can prevent or delay the rate of cognitive decline in 
AD patients has led to the establishment of clinical trials [14]. However, large-scale double-blind 
placebo-controlled clinical trials have not supported the use of NSAIDS in treating established AD 
[11].  The disappointing outcome of these clinical trials has raised questions as to our understanding 
of mechanisms and pathways that link systemic inflammation and neurodegeneration, and 
prompted questions about whether NSAIDs can act only as preventative agents following long term 
use, and whether their clinical failure to treat established AD has resulted from inappropriate 
choices of NSAIDs and the doses employed. 
The article by Xiuzhe et al., 2020 in Journal of Alzheimer’s disease is timely in reporting that levels of 
the plasma LXA4 were significantly reduced in post-stroke cognitive impairment (PSCI) patients 
compared with post-stroke non-cognitive impairment (PSNCI) patients [15]. This work has 
implications not only for the management of post stroke events, but also for conditions such as 
metabolic diseases [16], and diabetic chronic kidney disease [17], lupus nephritis [18] that increase 
risk of stroke in which similar low serum level of LXA4 is reported. There is growing interest to 
validate low LXA4 as a biomarker for inflammatory diseases as indicated by clinical trials such as 
COPD (id: NCT03609541) and asthma (id: NCT01898767 and NCT03423693).  
Xiuzhe et al., found that the formation of plasma LXA4 and the ratio of LXA4/LTB4 were positively 
correlated with Mini-Mental State Examination scores within the first 7 days of stroke onset. The 
study design was careful not to include any persons with previous known cognitive decline. 
Interestingly, lower levels were not observed for other SPMs such as resolvin D1, resolvin D2 or 
maresin1, highlighting the suitability of LXA4 as a biomarker for cognitive decline. As the authors 
suggest, the mechanisms behind the decreased formation of plasma LXA4 and any contribution to 
PSCI pathogenesis has yet to be explored. It is possible that LXA4 regulates polarization of microglia 
to M2 phenotype and may enhance neuronal survival against Aβ toxicity, reduce tau 
phosphorylation and reduce Aβ secretion but lower rates of formation in PSCI patients compromise 
its protective effects driving towards neuronal damage and cognitive decline. Longitudinal data for 
such a study will be able to shed more light into circulatory level of LXA4 and cognitive health in post-
stroke patients. Other in vivo studies supported that intravenous treatment with lipoxin analogues 
that resist metabolic degradation can provide neuroprotection and reduce neurobehavioral deficits 
at 4 weeks after ischemic stroke in rats [19]. In addition to LXA4, the ability of other SPMs such as 
resolvins and maresins to reduce inflammation in AD has also been described previously [13, 20]. 
Based on these common observations, the possibilities of developing novel “resolution-targeted” 
therapy is being investigated.  
Initial efficacy studies for early analogues of LXA4 studies have now been developed into four 
generations of LXA4 drug analogues: 1st generation- stable analogues of LXA4 [21], 2nd generation- 3-
oxa-LXA4 analogues [22], [23], [24], 3rd generation- pyridine/benzo-LXA4 analogues [25], [26] and 4th 
generation- Imidazole- and Oxazole-Containing Synthetic Lipoxin A4Mimetics (SLXms) [27]. These are 
being studied in various biological systems and a phase I trial is ongoing to evaluate the safety and 
efficacy of the LX analogue BLXA4-ME as an oral rinse for gingivitis (id: NCT02342691). Another 
study, ASTHMIRINE trial (id: NCT02906761, phase 3, n = 180) investigates the ability of Aspirin to 
enhance SPM formation with special attention to aspirin triggered LXA4, which is an epimer of LXA4. 
Even though these investigations are at early stage, they showcase the importance of future 
research for targeting LXA4 in common inflammatory diseases.  
The next challenges will be to understand the timing of the treatment for patients with cognitive 
impairment, and optimal drug doses, pharmacodynamics and pharmacokinetics. Research 
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developments to improve resolution of inflammation could lead to combat not only 
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